Abstract 1110
Background
Several studies have dealt with the risk factors for prediction of cisplatin-induced acute kidney injury (AKI), such as female, hypoalbuminemia, hypopotassemia, hypomagnesemia, complications of cardiovascular disease, diabetes mellitus, advancerd cancer, total amount of cisplatin use and the combination of paclitaxel. However, these reports were retrospectively examined and their analyses were based on several differing definitions of renal injury. Therefore, the risk factors for cisplatin-induced AKI have not yet been identified.
Methods
We conducted the pilot study to aim at screening for the risk factors that would be suitable for future prospective trial. Patients with solid tumor who had received cisplatin (≧50 mg/m2)-containing chemotherapy as the first-line treatment were eligible for the study. We investigated the occurrece of AKI and its association with the baseline characteristics and their laboratory test results during the treatment. AKI was defined as the increase of serum creatinine level>0.3 mg/dL, or × 1.5-2 at baseline, according to NCI-CTCAE v4.0. Gene polymorphisms of organic cation transporter (OCT2), which is reported to affect cisplatin-induced renal injury, were analyzed with DMET Plus.
Results
From December 2014 through June 2016, a total of 28 patients (22 males and 6 females) were enrolled. Their baseline characteristics were as follows: the median age was 65 years (range 55 to 77), and the median pretreatment serum creatinine level was 0.73 mg/dL. Tumor types were esophageal carcinoma (21 patients), gastric carcinoma (4 patients), and others (3 patients). Of 28 enrolled patients, AKI occurred in 8 patients (28.6%) and most of all developed AKI within 11 days after the start of chemotherapy. Univariate analysis showed that the level of serum cystatine C, urine β-2 microglobulin and body surface area were significantly higher in the AKI group (p
Conclusions
Our study suggested that serum cystatine C, urine β-2 microglobulin and body surface area may be the risk factors related to cisplatin-induced AKI.
Clinical trial identification
Legal entity responsible for the study
N/A
Funding
None
Disclosure
All authors have declared no conflicts of interest.